What if a dosage form could improve patient experience, support treatment adherence, and create new commercial opportunities at the same time? That opportunity is increasingly being realised through orodispersible tablets (ODTs), also known as orally disintegrating tablets. According to recent market analysis, the global ODT market is expected to grow at a Compound Annual Growth Rate (CAGR) of approximately 6.4%, with Europe emerging as one of the fastest-growing regions driven by ageing populations, chronic disease prevalence, and demand for patient-centric medicines2,3. For pharmaceutical manufacturers, CDMO partners, and healthcare innovators, ODTs are becoming more than a formulation choice - they are a strategic growth opportunity.
The growing adoption of ODTs is being driven by a combination of demographic, healthcare, and pharmaceutical industry trends.
What's Driving Growth?
The demand for ODTs is creating significant commercial opportunities for pharmaceutical companies, driven by innovation, market differentiation, and growing patient demand.
| Current Market | Future Market | Growth Rate |
|---|---|---|
| USD 15.85 Billion (2025) | USD 30.08 Billion (2034) | 7.38% CAGR (2026–2034) |
| Therapeutic Area | Key Applications |
|---|---|
| CNS & Psychiatric Disorders | Schizophrenia, Depression, Parkinson's Disease |
| Pain & Migraine Management | Migraine, Acute Pain Relief |
| Paediatric Therapies | Allergy, Fever, Infection Management |
| Geriatric Care | Neurological and Long-Term Therapies |
For pharmaceutical companies, ODTs offer more than improved patient convenience. They can help,
As healthcare systems across the UK and Europe continue to prioritise patient-centric medicines, ODTs are becoming an increasingly important area of innovation and commercial growth.
ODTs are expanding beyond traditional therapies, with increasing interest in cardiovascular, gastrointestinal, allergy, and chronic disease medicines alongside established CNS applications.
Pharmaceutical development is increasingly focused on improving the overall treatment experience, making dosage-form selection an important part of product strategy.
New advances in taste-masking, excipients, and manufacturing technologies are enabling a wider range of molecules to be successfully formulated as ODTs.
Regulators are placing greater emphasis on medicine usability, patient engagement, and product quality throughout pharmaceutical development.
As formulation technologies become more specialised, pharmaceutical companies are increasingly collaborating with experienced development and manufacturing partners to reduce development timelines and bring products to market more efficiently.
The next phase of ODT growth will be driven by innovation, patient-centric drug delivery, and strategic development partnerships. Companies that invest early in ODT capabilities will be better positioned to capture opportunities across the UK and European markets.
As the ODT market continues to grow across the UK and Europe, three factors will shape future success:
Developing medicines that are easier and more convenient for patients to take.
Expanding the possibilities for ODT development across more therapeutic areas.
Leveraging specialised expertise to accelerate development and manufacturing.
ODTs are no longer just an alternative dosage form. They are becoming a valuable tool for product differentiation, lifecycle management, and long-term commercial growth in an increasingly competitive pharmaceutical market.
As demand for ODTs continues to grow across the UK and Europe, pharmaceutical companies need partners with proven expertise in patient-centric drug delivery.
At NOVUMGEN, ODTs are a core area of focus. Our expanding ODT portfolio spans CNS, psychiatric, cardiovascular, allergy, and neurological therapies, supporting evolving patient and market needs.
Supporting the development of innovative and patient-friendly formulations.
ODT solutions across multiple high-demand therapy areas.
Focused on delivering reliable, high-quality pharmaceutical products.
Supporting licensing, development, and market expansion opportunities.
As ODT adoption continues to accelerate, NOVUMGEN is committed to helping pharmaceutical partners bring differentiated, patient-focused medicines to market through innovation, quality, and collaboration.
The growing adoption of ODTs reflects a broader shift towards patient-centric drug delivery and value-added pharmaceutical formulations. As demand continues to expand across the UK and Europe, ODTs are creating new opportunities for innovation, product differentiation, and sustainable growth across multiple therapeutic areas.
For pharmaceutical companies seeking to enhance patient experience, strengthen competitive positioning, and unlock new growth opportunities, ODTs represent one of the most promising formulation strategies in today's evolving healthcare landscape.